

# Anti-BCMA & CD3 Reference Antibody (Alnuctamab)

Catalog # APR11581

## Product Information


|                   |                                                                |
|-------------------|----------------------------------------------------------------|
| Application       | Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA |
| Primary Accession | <a href="#">Q02223 &amp; P07766</a>                            |
| Reactivity        | Human                                                          |
| Clonality         | Bispecific                                                     |
| Isotype           | IgG-Fab                                                        |

## Additional Information


|                    |                             |
|--------------------|-----------------------------|
| Target/Specificity | TNFRSF17 / BCMA / CD269,CD3 |
| Expression system  | CHO                         |

## Protein Information

## Images




Anti-BCMA & CD3 Reference Antibody (Alnuctamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-BCMA & CD3 Reference Antibody (Alnuctamab) is 100.00%, determined by SEC-HPLC.



Alnuctamab bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Alnuctamab bound to huBCMA-ECD-His, and the EC50 was 0.042 nM.




Alnuctamab bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Alnuctamab bound to huBCMA-HEK293 cells, and the EC50 was 0.693 nM.



Alnuctamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Alnuctamab bound to huCD3e-jurkat cells, and the EC50 was 66.190 nM.



Co-incubation of Alnuctamab with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Alnuctamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.110 nM.



The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Alnuctamab) is 192.13 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.